Chinese experts on Monday have confirmed that an antimalarial drug, Chloroquine Phosphate, has certain curative effect, based on the result of clinical trials, has a certain curative effect on the novel coronavirus disease (COVID-19).
Sun Yanrong, the deputy head of the China National Center for Biotechnology Development at a press conference said experts have “unanimously” suggested the drug be included in the next version of the treatment guidelines and applied in wider clinical trials as soon as possible.
According to her, Chloroquine has been under clinical trials in over 10 hospitals in Beijing, Guangdong Province and central China’s Hunan Province, and it has shown fairly good efficacy.
In the trials done, patients who had taken the drug have shown better results than others.
Sun gave an example of a 54-year-old patient in Beijing, who was admitted to hospital four days after showing symptoms. After taking the drug for a week, he saw all indicators improve and the nucleic acid turn negative.
Chloroquine Phosphate was selected from tens of thousands of existing drugs after multiple rounds of screening. Other drugs also recommended are Remdesivir and Fapilavir.